Morphine-6-glucuronide - PAION

Drug Profile

Morphine-6-glucuronide - PAION

Alternative Names: CEE 04410; M6G

Latest Information Update: 01 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CeNeS Pharmaceuticals
  • Developer PAION; Yichang Humanwell Pharmaceutical
  • Class Morphine derivatives; Opioid analgesics
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase Unknown Postoperative pain

Most Recent Events

  • 05 Nov 2014 Morphine-6-glucuronide licensed to Yichang Humanwell Pharmaceutical in China
  • 03 Nov 2008 Adverse events data from a Meta-analysis of Phase-II and Phase-III trials in Postoperative pain released by PAION
  • 24 Jun 2008 CeNeS has been acquired by PAION
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top